Downregulation of hepatoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 1016-1025

  Tsai, Han En ^a   Liu, Guei Sheung ^e   Kung, Mei Lang ^b   Liu, Li Feng ^c   Wu, Jian Ching ^a   Tang, Chia Hua ^d   Huang, Ching Hui ^a   Chen, San Cher ^a   Lam, Hing Chung ^d   Wu, Chieh Shan ^d   Tai, Ming Hong ^a,d  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SMOOTH MUSCLE ACTIN; ANTIMETASTATIC AGENT; BETA INTERMEDIN; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOTROPIN; FIBRONECTIN; HEPATOMA DERIVED GROWTH FACTOR; MESSENGER RNA; PROOPIOMELANOCORTIN; THYMOSIN BETA4; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; METASTATIC MELANOMA; MICROARRAY ANALYSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PRO-OPIOMELANOCORTIN;

EID: 84879174694     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0832     Document Type: Article

References (46)

1. Melnikova VO, Bar-Eli M. Inflammation and melanoma metastasis. Pigment Cell Melanoma Res 2009;22:257-67.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
3. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70.
4. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet 2009;374:362-5.
5. Crosby T, Fish R, Coles B, Mason MD. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000:CD001215.
6. Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989;183:273-84.
7. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994;269:25143-9.
8. Klagsbrun M, Sasse J, Sullivan R, Smith JA. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci U S A 1986; 83:2448-52.
9. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001;276: 37564-8.
10. Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 2003;98:1444-56.
11. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63:6716-25.
12. Lee KH, Choi EY, Kim MK, Lee SH, Jang BI, Kim TN, et al. Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res 2011;19:67-76.
13. Everett AD, Yang J, Rahman M, Dulloor P, Brautigan DL. Mitotic phosphorylation activates hepatoma-derived growth factor as a mitogen. BMC Cell Biol 2011;12:15.
14. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 2007;14: 2141-9.
15. Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, Kuo HM, et al. Hepatoma-Derived Growth Factor Regulates breast cancer cell invasion by Modulating Epithelial Mesenchymal Transition. J Pathol 2012;228: 158-69.
16. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesen-chymal transition. Cell Res 2009;19:156-72.
17. Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol 2012;22:455-61.
18. Nakamura M, Tokura Y. Epithelial-mesenchymal transition in the skin. J Dermatol Sci 2011;61:7-13.
19. Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2010;2:154-9.
20. Liu GS, Liu LF, Lin CJ, Tseng JC, Chuang MJ, Lam HC, et al. Gene transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway. Mol Pharmacol 2006;69: 440-51.
21. Liu GS, Tsai HE, Weng WT, Liu LF, Weng CH, Chuang MR, et al. Systemic pro-opiomelanocortin expression induces melanogenic differentiation and inhibits tumor angiogenesis in established mouse melanoma. Hum Gene Ther 2011;22:325-35.
22. Tsai HE, Liu LF, Dusting GJ, Weng WT, Chen SC, Kung ML, et al. Proopiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortin-1 receptor-independent pathway. J Gene Med 2012;14:44-53.
23. Smalley K, Eisen T. The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett 2000;476:198-202.
24. Smalley KS, Eisen TG. Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. Melanoma Res 2002;12: 187-92.
25. Kameyama K, Vieira WD, Tsukamoto K, Law LW, Hearing VJ. Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells. Int J Cancer 1990;45:1151-8.
26. Murata J, Ayukawa K, Ogasawara M, Fujii H, Saiki I. Alpha-melanocyte- stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 1997;17:82-93.
27. Kim A, Son M, Kim KI, Yang Y, Song EY, Lee HG, et al. Elevation of intracellular cyclic AMP inhibits NF-kappaB-mediated thymosin beta4 expression in melanoma cells. Exp Cell Res 2009;315: 3325-35.
28. Kao YH, Chen CL, Jawan B, Chung YH, Sun CK, Kuo SM, et al. Upregulation of hepatoma-derived growth factor is involved in murine hepatic fibrogenesis. J Hepatol 2010;52:96-105.
29. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436: 518-24.
30. Zhao H, Hastie T, Whitfield ML, Borresen-Dale AL, Jeffrey SS. Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. BMC Genomics 2002; 3:31.
31. Lam HC, Kuo SM, Chuang MJ, Keng HM, Lin PR, Liu GS, et al. Blockade of endothelin-1 release contributes to the anti-angiogenic effect by pro-opiomelanocortin overexpression in endothelial cells. Exp Biol Med (Maywood) 2006;231:782-8.
32. Yamamoto T, Nakamura H, Liu W, Cao K, Yoshikawa S, Enomoto H, et al. Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). J Gastroenterol 2009;44:228-35.
33. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 2002;99:10084-9.
34. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406: 532-5.
35. Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007;34:555-65.
36. Furuya M, Yonemitsu Y. Cancer neovascularization and proinflam-matory microenvironments. Curr Cancer Drug Targets 2008;8: 253-65.
37. Liu GS, Huang HT, Lin CJ, Shi JY, Liu LF, Tseng RT, et al. Prophylactic proopiomelanocortin expression alleviates capsaicininduced neurogenic inflammation in rat trachea. Shock 2009;32: 645-50.
38. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004;286: L1194-201.
39. Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008;14:199-209.
40. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008;19:294-308.
41. Bonitsis N, Batistatou A, Karantima S, Charalabopoulos K. The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 2006;28:187-93.
42. Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A, et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008;68:715-23.
43. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer 2011;105:231-8.
44. Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM. Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011;74:1002-14.
45. Guo Z, He Y, Wang S, Zhang A, Zhao P, Gao C, et al. Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol Rep 2011;26: 511-7.
46. Sedlmaier A, Wernert N, Gallitzendorfer R, Abouzied MM, Gieselmann V, Franken S. Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation. BMC Cancer 2011;11:457.